309 related articles for article (PubMed ID: 32763109)
1. Primary results from CECILIA, a global single-arm phase II study evaluating bevacizumab, carboplatin and paclitaxel for advanced cervical cancer.
Redondo A; Colombo N; McCormack M; Dreosti L; Nogueira-Rodrigues A; Scambia G; Lorusso D; Joly F; Schenker M; Ruff P; Estevez-Diz M; Irahara N; Donica M; Gonzalez-Martín A
Gynecol Oncol; 2020 Oct; 159(1):142-149. PubMed ID: 32763109
[TBL] [Abstract][Full Text] [Related]
2. A randomized phase II/III trial of conventional paclitaxel and carboplatin with or without bevacizumab versus dose-dense paclitaxel and carboplatin with or without bevacizumab, in stage IVB, recurrent, or persistent cervical carcinoma (JCOG1311): Primary analysis.
Ishikawa M; Shibata T; Iwata T; Nishio S; Takada T; Suzuki S; Horie K; Kudaka W; Kagabu M; Tanikawa M; Kitagawa R; Takekuma M; Kobayashi H; Yaegashi N;
Gynecol Oncol; 2021 Aug; 162(2):292-298. PubMed ID: 34016453
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial of paclitaxel, carboplatin, and bevacizumab for advanced or recurrent cervical cancer.
Suzuki K; Nagao S; Shibutani T; Yamamoto K; Jimi T; Yano H; Kitai M; Shiozaki T; Matsuoka K; Yamaguchi S
Gynecol Oncol; 2019 Sep; 154(3):554-557. PubMed ID: 31285082
[TBL] [Abstract][Full Text] [Related]
4. A randomized phase III trial of platinum chemotherapy plus paclitaxel with bevacizumab and atezolizumab versus platinum chemotherapy plus paclitaxel and bevacizumab in metastatic (stage IVB), persistent, or recurrent carcinoma of the cervix: the BEATcc study (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030).
Grau JF; Farinas-Madrid L; Oaknin A
Int J Gynecol Cancer; 2020 Jan; 30(1):139-143. PubMed ID: 31645423
[TBL] [Abstract][Full Text] [Related]
5. Bevacizumab in Metastatic, Recurrent, or Persistent Cervical Cancer: The BC Cancer Experience.
Tinker AV; Fiorino L; O'Dwyer H; Kumar A
Int J Gynecol Cancer; 2018 Oct; 28(8):1592-1599. PubMed ID: 30247250
[TBL] [Abstract][Full Text] [Related]
6. A single-arm study evaluating bevacizumab, cisplatin, and paclitaxel followed by single-agent bevacizumab in Japanese patients with advanced cervical cancer.
Sugiyama T; Mizuno M; Aoki Y; Sakurai M; Nishikawa T; Ueda E; Tajima K; Takeshima N
Jpn J Clin Oncol; 2017 Jan; 47(1):39-46. PubMed ID: 27803033
[TBL] [Abstract][Full Text] [Related]
7. Bevacizumab for recurrent, persistent or advanced cervical cancer: reproducibility of GOG 240 study results in "real world" patients.
Godoy-Ortiz A; Plata Y; Alcaide J; Galeote A; Pajares B; Saez E; Alba E; Sánchez-Muñoz A
Clin Transl Oncol; 2018 Jul; 20(7):922-927. PubMed ID: 29222647
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Bevacizumab-Containing Therapy in Newly Diagnosed Ovarian Cancer: ROSiA Single-Arm Phase 3B Study.
Oza AM; Selle F; Davidenko I; Korach J; Mendiola C; Pautier P; Chmielowska E; Bamias A; DeCensi A; Zvirbule Z; González-Martín A; Hegg R; Joly F; Zamagni C; Gadducci A; Martin N; Robb S; Colombo N
Int J Gynecol Cancer; 2017 Jan; 27(1):50-58. PubMed ID: 27749456
[TBL] [Abstract][Full Text] [Related]
9. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240).
Tewari KS; Sill MW; Penson RT; Huang H; Ramondetta LM; Landrum LM; Oaknin A; Reid TJ; Leitao MM; Michael HE; DiSaia PJ; Copeland LJ; Creasman WT; Stehman FB; Brady MF; Burger RA; Thigpen JT; Birrer MJ; Waggoner SE; Moore DH; Look KY; Koh WJ; Monk BJ
Lancet; 2017 Oct; 390(10103):1654-1663. PubMed ID: 28756902
[TBL] [Abstract][Full Text] [Related]
10. Paclitaxel-carboplatin and bevacizumab combination with maintenance bevacizumab therapy for metastatic, recurrent, and persistent uterine cervical cancer: An open-label multicenter phase II trial (JGOG1079).
Tanigawa T; Takeshima N; Ishikawa H; Nishio S; Usami T; Yamawaki T; Oishi T; Ihira K; Kato H; Goto M; Saito M; Taira Y; Yokoyama M; Shoji T; Kondo E; Mori A; Yokoi T; Iwasa-Inoue N; Hirashima Y; Nagasawa T; Takenaka M; Mikami M; Sugiyama T; Enomoto T
Gynecol Oncol; 2022 Jun; 165(3):413-419. PubMed ID: 35487773
[TBL] [Abstract][Full Text] [Related]
11. Weekly Paclitaxel and Carboplatin Plus Bevacizumab as First-Line Treatment of Metastatic Triple-Negative Breast Cancer. A Multicenter Phase II Trial by the Hellenic Oncology Research Group.
Saloustros E; Nikolaou M; Kalbakis K; Polyzos A; Christofillakis C; Kentepozidis N; Pistamaltzian N; Kourousis C; Vamvakas L; Georgoulias V; Mavroudis D
Clin Breast Cancer; 2018 Feb; 18(1):88-94. PubMed ID: 29153775
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety results from OCTAVIA, a single-arm phase II study evaluating front-line bevacizumab, carboplatin and weekly paclitaxel for ovarian cancer.
Gonzalez-Martin A; Gladieff L; Tholander B; Stroyakovsky D; Gore M; Scambia G; Kovalenko N; Oaknin A; Ronco JP; Freudensprung U; Pignata S;
Eur J Cancer; 2013 Dec; 49(18):3831-8. PubMed ID: 24007819
[TBL] [Abstract][Full Text] [Related]
13. Final analysis of a randomized phase II/III trial of conventional paclitaxel and carboplatin with or without bevacizumab versus dose-dense paclitaxel and carboplatin with or without bevacizumab, in stage IVB, recurrent, or persistent cervical carcinoma (JCOG1311).
Ishikawa M; Shibata T; Kataoka T; Takekuma M; Kobayashi H; Yaegashi N; Satoh T;
Int J Gynecol Cancer; 2023 May; 33(5):692-700. PubMed ID: 36997229
[TBL] [Abstract][Full Text] [Related]
14. Phase I clinical trial of weekly paclitaxel, weekly carboplatin, and concurrent radiotherapy for primary cervical cancer.
Rao GG; Rogers P; Drake RD; Nguyen P; Coleman RL
Gynecol Oncol; 2005 Jan; 96(1):168-72. PubMed ID: 15589596
[TBL] [Abstract][Full Text] [Related]
15. Carboplatin-paclitaxel compared to Carboplatin-Paclitaxel-Bevacizumab in advanced or recurrent endometrial cancer: MITO END-2 - A randomized phase II trial.
Lorusso D; Ferrandina G; Colombo N; Pignata S; Pietragalla A; Sonetto C; Pisano C; Lapresa MT; Savarese A; Tagliaferri P; Lombardi D; Cinieri S; Breda E; Sabatucci I; Sabbatini R; Conte C; Cecere SC; Maltese G; Scambia G
Gynecol Oncol; 2019 Dec; 155(3):406-412. PubMed ID: 31677820
[TBL] [Abstract][Full Text] [Related]
16. Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study.
Walker JL; Brady MF; Wenzel L; Fleming GF; Huang HQ; DiSilvestro PA; Fujiwara K; Alberts DS; Zheng W; Tewari KS; Cohn DE; Powell MA; Van Le L; Davidson SA; Gray HJ; Rose PG; Aghajanian C; Myers T; Alvarez Secord A; Rubin SC; Mannel RS
J Clin Oncol; 2019 Jun; 37(16):1380-1390. PubMed ID: 31002578
[TBL] [Abstract][Full Text] [Related]
17. Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial.
Pignata S; Lorusso D; Joly F; Gallo C; Colombo N; Sessa C; Bamias A; Salutari V; Selle F; Frezzini S; De Giorgi U; Pautier P; Bologna A; Orditura M; Dubot C; Gadducci A; Mammoliti S; Ray-Coquard I; Zafarana E; Breda E; Favier L; Ardizzoia A; Cinieri S; Largillier R; Sambataro D; Guardiola E; Lauria R; Pisano C; Raspagliesi F; Scambia G; Daniele G; Perrone F;
Lancet Oncol; 2021 Feb; 22(2):267-276. PubMed ID: 33539744
[TBL] [Abstract][Full Text] [Related]
18. A randomized, controlled trial evaluating the efficacy and safety of BTH1677 in combination with bevacizumab, carboplatin, and paclitaxel in first-line treatment of advanced non-small cell lung cancer.
Engel-Riedel W; Lowe J; Mattson P; Richard Trout J; Huhn RD; Gargano M; Patchen ML; Walsh R; Trinh MM; Dupuis M; Schneller F
J Immunother Cancer; 2018 Feb; 6(1):16. PubMed ID: 29486797
[TBL] [Abstract][Full Text] [Related]
19. Bevacizumab combined with platinum-taxane chemotherapy as first-line treatment for advanced ovarian cancer: a prospective observational study of safety and efficacy in Japanese patients (JGOG3022 trial).
Komiyama S; Kato K; Inokuchi Y; Takano H; Matsumoto T; Hongo A; Asai-Sato M; Arakawa A; Kamiura S; Tabata T; Takeshima N; Sugiyama T
Int J Clin Oncol; 2019 Jan; 24(1):103-114. PubMed ID: 30030657
[TBL] [Abstract][Full Text] [Related]
20. A retrospective analysis of cisplatin/carboplatin plus paclitaxel in advanced or recurrent cervical cancer.
Song D; Kong W; Zhang T; Han C; Liu T; Jiao S; Chen J
J Obstet Gynaecol; 2019 Apr; 39(3):389-394. PubMed ID: 30663464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
